ALKS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alkermes Plc is not a strong buy at this moment for a beginner investor with a long-term strategy. The company's recent financial performance shows declining revenue, net income, and EPS, which raises concerns about its growth trajectory. Additionally, insider selling activity and lack of strong technical or proprietary trading signals further suggest caution. While the company's long-term prospects in its narcolepsy franchise may be promising, the current data does not support an immediate buy decision.
The MACD is negative and expanding (-0.456), indicating bearish momentum. RSI is at 28.761, close to oversold territory but still neutral. Moving averages are converging, showing no clear trend. The stock is trading near its key support level of 30.411, with resistance at 33.818.
The company is shifting focus to its emerging narcolepsy franchise, with products like Lumryz and alixorexant showing potential. Analysts have highlighted long-term growth prospects in this area.
No recent congress trading data or strong proprietary trading signals.
In Q4 2025, revenue dropped by 10.57% YoY to $384.5 million. Net income fell by 66.32% YoY to $49.34 million. EPS declined by 67.05% YoY to $0.29. Gross margin improved slightly to 87.98%, up 2.84% YoY.
Analysts are mixed. Wolfe Research initiated an Outperform rating with a $45 price target, citing potential in the narcolepsy franchise. H.C. Wainwright lowered the price target to $43 from $46, maintaining a Neutral rating. BofA raised the price target to $34, also with a Neutral rating, reflecting cautious optimism.
